Kecioren Education and Training Hospital
Ankara, Kecioren, 06380, Turkey (Türkiye)
NCT Number: NCT00733473
The purpose of this study is to determine if adding nebulized budesonide to the systemic steroid for treatment of acute wheezing has any additive benefit in children who have hospitalized for acute wheezing.
Looking for future studies?
Notify Me6 month–6 year
All sexes
Interventional
Phase 4
Ankara, Kecioren, 06380, Turkey (Türkiye)
Context: Inhaled steroids reduced admission rates in patients with acute asthma, but it is unclear if there is a benefit of inhaled corticosteroids when used in addition to systemic corticosteroids. There is insufficient evidence that inhaled corticosteroids result in clinically important changes in pulmonary function or clinical scores when used in acute asthma. Similarly, it was mentioned in the Cochrane Database of Systematic Reviews that further research is needed to clarify if there is a benefit of inhaled corticosteroids when used in addition to systemic steroids.
Objective: To determine if adding nebulized budesonide to the systemic steroid for treatment of acute wheezing in hospitalized children has any benefit on, symptom score, duration of hospitalization and time to discharge from hospital.
Study Design/Setting/Participants: A double-blind, randomized, controlled trial of nebulized budesonide versus placebo for children 6 months to 6 years of age who have admitted to the hospital for acute wheezing.
Intervention: Participants will receive standard therapy including SCS, albuterol, and ipratropium bromide and will be randomly assigned to also receive either nebulized BIS or saline.
Study Measures: Differences in asthma scores, vital signs, duration of hospitalization and time to discharge from hospital will be compared between treatment groups.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
Other names: Pulmicort 0.5 mg/ml nebules
Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
Time frame: 1-5 days
Time frame: 1 to 5 days
Time frame: 1 to 5 days
Time frame: 1 to 5 days
Time frame: 1 to 5 days
Kecioren Education and Training Hospital
Other
Phase 4 Study of Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00733317
Acute Asthma, Asthma
Ankara, Kecioren, Turkey (Türkiye)
View Trial DetailsNCT02148796
Asthma, Bronchial Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05194436
Asthma, Bronchial Diseases
Singapore
View Trial DetailsNCT03203603
Asthma, Bronchial Diseases
Indianapolis, Indiana, United States
View Trial Details